AOXG.US Aoxing Pharmaceutical Company Inc
- Market cap
- USD 877K
- P/E
- -
- P/B
- 0.07x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is AOXG.US undervalued?
Graham numberThe Graham number of Aoxing Pharmaceutical Company Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Aoxing Pharmaceutical Company Inc fundamental analysis
No fundamental analysis for Aoxing Pharmaceutical Company Inc yet.
Aoxing Pharmaceutical Company Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Aoxing Pharmaceutical Company Inc
Aoxing Pharmaceutical Company, Inc. a specialty pharmaceutical company, engages in research and development, manufacture, and distribution of narcotic, pain-management, and addiction treatment pharmaceutical products primarily in the People's Republic of China. The company's principal products include Zhongtong'an, a capsule of herbal extraction for the indication of oral and dental pain; and Yiqi Qiangshen Granule, an OTC herbal extraction for tonifying qi and empowering bo…
Full company profileAoxing Pharmaceutical Company Inc financial statements
Aoxing Pharmaceutical Company Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2015 | 2016 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 25.5M | 32.3M | - | - | - | - | - | - | - | 33.5K |
| Gross Profit | 19.8M | 24.6M | - | - | - | - | - | - | - | 33.3K |
| Operating Income | 8.70M | 6.23M | - | - | - | - | - | -14.8K | -7.30K | -23.1K |
| EBITDA | 9.36M | 7.25M | - | - | - | - | - | -14.8K | 55.2K | -23.1K |
| Net Income | 5.49M | 2.06M | - | - | - | - | - | -14.8K | 55.2K | -23.4K |
| EPS | 0.09 | 0.03 | - | - | - | - | - | 0.00 | 0.00 | 0.00 |
| Balance Sheet | ||||||||||
| Total Assets | 53.0M | 56.2M | - | - | - | - | - | - | - | - |
| Total Liabilities | 43.0M | 38.2M | - | - | - | - | - | - | - | - |
| Shareholders' Equity | 11.2M | 19.1M | - | - | - | - | - | - | - | - |
| Cash & Short-term Investments | 5.37M | 6.91M | - | - | - | - | - | - | - | - |
| Total Debt | 31.8M | 25.5M | - | - | - | - | - | - | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | 3.03M | -535K | - | - | - | - | - | -14.8K | 23.8K | -103K |
| Capital Expenditure | 2.71M | 118K | - | - | - | - | - | 0.00 | 5.00 | 0.00 |
| Free Cash Flow | 320K | -653K | - | - | - | - | - | -14.8K | 23.8K | -103K |
| Ratios | ||||||||||
| ROE | 48.9% | 10.8% | - | - | - | - | - | - | - | - |
| ROA | 10.4% | 3.7% | - | - | - | - | - | - | - | - |
| Net Profit Margin | 21.6% | 6.4% | - | - | - | - | - | - | - | -69.8% |
| Debt to Equity | 2.83x | 1.33x | - | - | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Aoxing Pharmaceutical Company Inc dividends
Aoxing Pharmaceutical Company Inc has not paid dividends in the last 10 fiscal years.
Last stock split: 1:2 on Mar 29, 2010.
Who owns Aoxing Pharmaceutical Company Inc
Ownership data of Aoxing Pharmaceutical Company Inc is not available yet.
Aoxing Pharmaceutical Company Inc company profile
- Company name
- Aoxing Pharmaceutical Company Inc
- Ticker
- AOXG.US
- Exchange
- USA Stocks
- Listed since
- Oct 7, 1999
- Sector
- Financial Services
- Industry
- Pharmaceuticals
- Employees
- 346
- Fiscal year end
- June
- Address
- 1098 Foster City Blvd, Foster City, CA, United States, 94404
- Phone
- 646 367 1747
- Website
- axzyen.icm.cn
About Aoxing Pharmaceutical Company Inc
Aoxing Pharmaceutical Company, Inc. a specialty pharmaceutical company, engages in research and development, manufacture, and distribution of narcotic, pain-management, and addiction treatment pharmaceutical products primarily in the People's Republic of China. The company's principal products include Zhongtong'an, a capsule of herbal extraction for the indication of oral and dental pain; and Yiqi Qiangshen Granule, an OTC herbal extraction for tonifying qi and empowering body, and promoting blood circulation to remove meridian obstruction, as well as Tilidine hydrochloride, an orally-absorbed synthetic narcotic analgesic tablet used in 50mg or 100mg dosage for relief of acute, moderate to severe pain, and chronic cancer-related pain. Its products under development comprise Oxycodone and Acetaminophen tablets and capsules, which has completed clinical trials for the treatment of acute and chronic pain; Buprenorphine/Naloxone, a sublingual combo tablet that has completed Phase II clinical trials for the treatment of opioid dependence; and Tilidine/Naloxone, a compound capsule which is in Phase II clinical trial to treat acute and chronic pain. The company was formerly known as China Aoxing Pharmaceutical Company, Inc. and changed its name to Aoxing Pharmaceutical Company, Inc. in March 2010. Aoxing Pharmaceutical Company, Inc. was incorporated in 1996 and is based in Foster City, California.
Aoxing Pharmaceutical Company Inc management
2- Mr. Zhenjiang YueChairman and Chief Executive Officer · born 1959
- Mr. Guoan ZhangChief Accounting Officer & Senior VP of Finance · born 1970